HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sandy, J. Articles by Noble, M. Search for Related Content PubMed PubMed Citation Articles by Sandy, J. Articles by Noble, M. Social Bookmarking                   What's this?

Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis

¹ Department of Pharmacology and
² Department of Molecular Biophysics, Oxford University, Oxford, OX1 3QT, United Kingdom

(RECEIVED October 6, 2004; FINAL REVISION November 17, 2004; ACCEPTED November 19, 2004)

Isoniazid is a frontline drug used in the treatment of tuberculosis (TB). Isoniazid is a prodrug, requiring activation in the mycobacterial cell by the catalase/peroxidase activity of the katG gene product. TB kills two million people every year and the situation is getting worse due to the increase in prevalence of HIV/AIDS and emergence of multidrug-resistant strains of TB. Arylamine N-acetyltransferase (NAT) is a drug-metabolizing enzyme (E.C. 2.1.3.5). NAT can acetylate isoniazid, transferring an acetyl group from acetyl coenzyme A onto the terminal nitrogen of the drug, which in its N-acetylated form is therapeutically inactive. The bacterium responsible for TB, Mycobacterium tuberculosis, contains and expresses the gene encoding the NAT protein. Isoniazid binds to the NAT protein from Salmonella typhimurium and we report here the mode of binding of isoniazid in the NAT enzyme from Mycobacterium smegmatis, closely related to the M. tuberculosis and S. typhimurium NAT enzymes. The mode of binding of isoniazid to M. smegmatis NAT has been determined using data collected from two distinct crystal forms. We can say with confidence that the observed mode of binding of isoniazid is not an artifact of the crystallization conditions used. The NAT enzyme is active in mycobacterial cells and we propose that isoniazid binds to the NAT enzyme in these cells. NAT activity in M. tuberculosis is likely therefore to modulate the degree of activation of isoniazid by other enzymes within the mycobacterial cell. The structure of NAT with isoniazid bound will facilitate rational drug design for anti-tubercular therapy.

Keywords: arylamine N-acetyltransferase; isoniazid; tuberculosis; drug design

Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.041163505.

Reprint requests to: James Sandy, Department of Pharmacology, Oxford University, Mansfield Road, Oxford, OX1 3QT, United Kingdom; e-mail: james.sandy{at}pharm.ox.ac.uk; fax: +44-1865-271853.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Wu, L. Dombrovsky, W. Tempel, F. Martin, P. Loppnau, G. H. Goodfellow, D. M. Grant, and A. N. Plotnikov Structural Basis of Substrate-binding Specificity of Human Arylamine N-Acetyltransferases J. Biol. Chem., October 12, 2007; 282(41): 30189 - 30197. [Abstract] [Full Text] [PDF]